{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:32Z","timestamp":1794047432271,"version":"4.8.0"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"12","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2022.282228","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T07:44:33Z","timestamp":1682581473000},"page":"3506-3510","source":"Crossref","is-referenced-by-count":2,"title":["Myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangements of &lt;i&gt;PCM1::JAK2&lt;\/i&gt; with erythroblastic sarcoma: a case report and literature review"],"prefix":"10.3324","volume":"108","author":[{"given":"Lina","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiying","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"55551","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-2405.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"55552","doi-asserted-by":"crossref","unstructured":"King RL, Siaghani PJ, Wong K. Novel t(1;8)(p31.3;q21.3) NFIA-RUNX1T1 translocation in an infant erythroblastic sarcoma. Am J Clin Pathol. 2021; 156(1):129-138.","DOI":"10.1093\/ajcp\/aqaa216"},{"key":"55553","doi-asserted-by":"crossref","unstructured":"Tomlinson B, Raess PW, Beck RC. Erythroblastic sarcoma with rare PDGFRA rearrangement responding to tyrosine kinase inhibitor therapy. Br J Haematol. 2020; 188(6):e98-e100.","DOI":"10.1111\/bjh.16379"},{"key":"55554","doi-asserted-by":"crossref","unstructured":"Nozuchi N, Nakaya Y, Ishii N. Erythroblastic sarcoma coexistent with myelodysplastic syndrome. Pathol Int. 2019; 69(8):505-507.","DOI":"10.1111\/pin.12835"},{"key":"55555","doi-asserted-by":"crossref","unstructured":"Luedke C, Rein L. Transformation to erythroblastic sarcoma from myeloid neoplasm with PCM1-JAK2. Blood. 2020; 136(9):1113.","DOI":"10.1182\/blood.2019004410"},{"key":"55556","doi-asserted-by":"crossref","unstructured":"Rizzuto G, Leoncin M, Imbergamo S. Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive myeloid sarcoma and acute B-lymphoblastic leukemia. Clin Case Rep. 2022; 10(1):e05212.","DOI":"10.1002\/ccr3.5212"},{"key":"55557","doi-asserted-by":"crossref","unstructured":"Song I, Lee DH, Lee JH. A t(8;9)(p22;p24)\/PCM1-JAK2 translocation in a patient with myeloproliferative neoplasm and myeloid sarcoma: first report in Korea. Ann Lab Med. 2016; 36(1):79-81.","DOI":"10.3343\/alm.2016.36.1.79"},{"key":"55558","doi-asserted-by":"crossref","unstructured":"Kaplan HG, Jin R, Bifulco CB. PCM1-JAK2 fusion tyrosine kinase gene-related neoplasia: a systematic review of the clinical literature. Oncologist. 2022; 27(8):e661-e670.","DOI":"10.1093\/oncolo\/oyac072"},{"key":"55559","doi-asserted-by":"crossref","unstructured":"Lierman E, Selleslag D, Smits S. Ruxolitinib inhibits transforming JAK2 fusion proteins In vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)\/PCM1-JAK2\u2013 positive chronic eosinophilic leukemia. Blood. 2012; 120(7):1529-1531.","DOI":"10.1182\/blood-2012-06-433821"},{"key":"55560","doi-asserted-by":"crossref","unstructured":"Tang GL, Philip JKSS, Weinberg O. Hematopoietic neoplasms with 9p24\/JAK2 rearrangement: a multicenter study. Mod Pathol. 2019; 32(4):490-498.","DOI":"10.1038\/s41379-018-0165-9"},{"key":"55561","doi-asserted-by":"crossref","unstructured":"Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021; 96(1):145-162.","DOI":"10.1002\/ajh.26050"},{"key":"55562","doi-asserted-by":"crossref","unstructured":"Kuo MC, Liang DC, Huang CF. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia. 2009; 23(8):1426-1431.","DOI":"10.1038\/leu.2009.48"},{"key":"55563","doi-asserted-by":"crossref","unstructured":"Pozdnyakova O, Orazi A, Kelemen K. Myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangements of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2. Am J Clin Pathol. 2021; 155(2):160-178.","DOI":"10.1093\/ajcp\/aqaa208"},{"key":"55564","doi-asserted-by":"crossref","unstructured":"Kumar KR, Chen W, Koduru PR. Myeloid and lymphoid neoplasm with abnormalities of FGFR1 presenting with trilineage blasts and RUNX1 rearrangement: a case report and review of literature. Am J Clin Pathol. 2015; 143(5):738-748.","DOI":"10.1309\/AJCPUD6W1JLQQMNA"},{"key":"55565","doi-asserted-by":"crossref","unstructured":"Baer C, Muehlbacher V, Kern W. Molecular genetic characterization of myeloid\/ lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2. Haematologica. 2018; 103(8):e348-e350.","DOI":"10.3324\/haematol.2017.187302"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282228\/75598","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282228\/76364","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11063\/75598","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:00Z","timestamp":1794045840000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.282228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":15,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.282228","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,27]]}}}